Repligen sold the last vestiges of its drug pipeline to BioMarin as it finishes its exit as a therapeutic developer and manufacturer. In the deal, BioMarin acquires Repligen's histone deacetylase inhibitors (HDACs) intended to target rare diseases, like Friederich's ataxia. The deal only requires BioMarin to pay $2 M upfront and commit to potential milestones of another $160 M if the drugs reach the market. BioMarin of course is a successful developer and marketer of rare and orphan drugs.
Repligen completes its exit from drug development and will continue to make products used in biopharmaceutical production, like protein A for mAb purification. They also continue to sell the portfolio acquired from Novozymes in 2011 -- products like LongR3 IGF. See Xconomy.
Posted by Bruce Lehr Jan 21st 2014.